The stock market is up 27% ahead of the final Fed meeting of the year. But is a correction overdue? The bubble in U.S.

Vivendi (Paris:VIV): As announced, the shares of Canal+, Havas NV and Louis Hachette group started trading on December 16 (th) on the London Stock Exchange, Euronext Amsterdam and Euronext Growth ...

Shares in Relief Therapeutics rose after it said a clinical trial of its protein-substitute treatment improved metabolic control. Shares in early trade were up 14% at 4.43 Swiss francs and have more ...

Dow Jones Industrial Average futures increased 47 points, or 0.11%, to 44,381 S&P 500 futures increased 5 points, or 0.08%, to 6,061 Nasdaq 100 futures increased 20.75 points, or 0.09%, to 22,102.5 On ...

GSK's potential cancer drug Jemperli cleared an important hurdle ahead of potentially receiving marketing permission from the European Medicines Agency.

CP Axtra said Friday it plans to spend 7.97 billion baht, equivalent to $233.6 million, on a 95% stake in a mall-and-office project in the Thai capital known as the Happitat. It said the deal will ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Shares in Galderma climbed after the company said the U.S. Food and Drug Administration approved its drug Nemluvio for the treatment of patients with atopic dermatitis. Shares in Galderma were 3.2% ...

Baloise said it appointed Andrea Kleiner as head of business clients at Baloise in Switzerland, effective April 1. The Swiss insurance company on Monday said that Kleiner will replace Patric Olivier ...

Ricardo said it agreed to the sale of its defense business for $85 million and that it will use the funds to acquire an initial stake in E3 Advisory.

Xlife Sciences plans to list its portfolio company Veraxa Biotech on the Nasdaq Stock Market in New York following a unanimously passed board resolution. The Swiss biotechnology company said Monday ...

The Spider-Man spinoff “Kraven the Hunter” got off to a disastrous start in North American theaters this weekend.